|Exelixis, Inc. at the European Society for Medical Oncology (ESMO) 2016 Congress|
Exelixis co-hosted an investor and media briefing at the ESMO 2016 Congress. During the 90 minute event, the company’s management team and invited guests reviewed data for cabozantinib presented at ESMO, including the results of the CABOSUN phase 2 randomized trial. The event also included a panel discussion with Drs. Toni K. Choueiri (Dana-Farber), Nizar Tannir (MD Anderson Cancer Center) and Sumanta Pal (City of Hope).